RADR

Dallas Biotech Launches Open-Access AI Tool Targeting One of Brain Drug Discovery’s Toughest Hurdles

by | Aug 20, 2025
With just 2% to 6% of small-molecule drugs able to cross the blood-brain barrier, researchers and drugmakers face steep odds. Lantern Pharma’s tool, the company’s CEO says, could be “a paradigm shift” in developing treatments for conditions ranging from brain cancers to Parkinson’s disease.
MORE
Lantern Pharma Adds VP of Clinical Development, Additional Team Members
by | Mar 2, 2023

Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....

MORE
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.

Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE